Leading integrated radiotherapy systems maker, Varian Medical Systems (VAR) recently disclosed that its TrueBeam radiotherapy delivery system, a new design of linear accelerator know-how, has clinched a prestigious overseas award for its design. The elegant and integrated TrueBeam system, which was commercialized last year, has been chosen for the well-known Red Dot award for product design.
Based in Essen, Germany, the Red Dot organization hands out annual prizes for design concept as well as product design. Companies from 60 nations enlisted close to 4,500 products for the current year. The winning entries were announced at a well organized awards function in Essen.
A spokesperson for the Red Dot award stated that the judges paid due attention to design quality along with providing recognition for creative and authentic solutions. These parameters are not only measures for excellence in design but also for potential commercial success.
The TrueBeam know-how is meant to treat tumors in an accurate and rapid fashion, including tumors that are mobile, as the patient breathes, during treatment. The system was created to treat different cancers such as breast, lungs and neck. It is capable of synchronizing in a dynamic manner, motion management, treatment delivery and the position of the patient. TrueBeam was engineered by the development team of Varian and its commercial design was accomplished in partnership with BMW Group DesignWorksUSA.
The TrueBeam system is capable of delivering a wide range of radiotherapy. Its domain includes image-guided intensity modulated and volumetric radiotherapy treatments as well as stereotactic radiosurgery and stereotactic body radiotherapy.
Given its high intensity mode, TrueBeam can provide extremely high doses at over twice the pace achieved by earlier generations of know-how. Since its commercialization in April 2010, Varian has received orders for more than 220 TrueBeam systems. The company has either installed, or in the process of installing, 65 systems around the globe.
Varian is the world’s leading manufacturer of integrated radiotherapy systems for treating cancer and a premier supplier of X-ray tubes for diagnostic imaging applications. In the radiation oncology market, the company competes head-to-head with Accuray Incorporated (ARAY).
Varian is poised to increase its market share in the radiation oncology market. The company is currently enjoying a healthy demand for its coveted RapidArc and TrueBeam radiotherapy technology. However, uncertainties stemming from health care reform and a still weak hospital capital spending environment across many developed countries, especially in Europe, pose headwinds. Currently, we have a Neutral recommendation on Varian.
ACCURAY INC (ARAY): Free Stock Analysis Report
Be the first to comment